Literature DB >> 12617465

Endothelial vasodilatory function is predicted by circulating apolipoprotein B and HDL in healthy humans.

Peter Steer1, Johannes Hulthe, Jonas Miligård, Dennis M Sarabi, Samar Basu, Bengt Vessby, Lars Lind.   

Abstract

Endothelium-dependent vasodilation (EDV), LDL particle size, and antibodies against oxidized LDL (oxLDLab) have been shown to be related to the development of atherosclerosis and cardiovascular disease. In this study, we investigated whether LDL particle size, oxLDLab, apolipoproteins, and lipoproteins are related to endothelial vasodilatory function in a population sample of 58 apparently healthy subjects aged 20 to 69 yr. EDV and endothelium-independent vasodilation (EIDV) were studied in the forearm during local administration of methacholine chloride (2 and 4 microg/min) or sodium nitroprusside (5 and 10 microg/min). Forearm blood flow was determined with venous occlusion plethysmography. In multiple stepwise regression analyses, neither oxLDLab nor small LDL particles were significantly predictive of endothelial vasodilatory function. Instead, a high level of apolipoprotein B (apoB) was an independent predictor of both attenuated EDV and EIDV (r = -0.43, P < 0.01, and r = -0.34, P < 0.05, respectively). HDL cholesterol, on the other hand, was the only lipid variable that was significantly related to the EDV to EIDV ratio, an index of endothelial vasodilatory function (r = 0.35, P < 0.01). The inverse associations between apoB and both EDV and EIDV indicate that apoB might be an early marker of structural vascular changes in healthy subjects, whereas HDL seems to be more specifically related to endothelial vasodilatory function.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12617465     DOI: 10.1007/s11745-002-1010-3

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  48 in total

1.  Autoantibodies to oxidized low density lipoprotein: the relationship to low density lipoprotein fatty acid composition in diabetes.

Authors:  M E Griffin; D McInerney; A Fraser; A H Johnson; P B Collins; D Owens; G H Tomkin
Journal:  Diabet Med       Date:  1997-09       Impact factor: 4.359

2.  Evaluation of endothelium-dependent vasodilation in the human peripheral circulation.

Authors:  L Lind; J Hall; A Larsson; M Annuk; B Fellström; H Lithell
Journal:  Clin Physiol       Date:  2000-11

3.  Oxidized lipoproteins inhibit endothelium-dependent vasodilation. Effects of pressure and high-density lipoprotein.

Authors:  J Galle; M Ochslen; P Schollmeyer; C Wanner
Journal:  Hypertension       Date:  1994-05       Impact factor: 10.190

4.  Antibody against oxidized low-density lipoprotein predicting myocardial infarction.

Authors:  M Puurunen; M Mänttäri; V Manninen; L Tenkanen; G Alfthan; C Ehnholm; O Vaarala; K Aho; T Palosuo
Journal:  Arch Intern Med       Date:  1994-11-28

5.  Effects of age, gender and metabolic factors on endothelium-dependent vasodilation: a population-based study.

Authors:  M Sarabi; J Millgård; L Lind
Journal:  J Intern Med       Date:  1999-09       Impact factor: 8.989

6.  Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia.

Authors:  J Hulthe; J Wikstrand; A Lidell; I Wendelhag; G K Hansson; O Wiklund
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-08       Impact factor: 8.311

7.  Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation.

Authors:  E Maggi; E Marchesi; V Ravetta; A Martignoni; G Finardi; G Bellomo
Journal:  J Hypertens       Date:  1995-01       Impact factor: 4.844

8.  Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL.

Authors:  S Ylä-Herttuala; W Palinski; S W Butler; S Picard; D Steinberg; J L Witztum
Journal:  Arterioscler Thromb       Date:  1994-01

9.  Low-density lipoprotein subclass patterns and risk of myocardial infarction.

Authors:  M A Austin; J L Breslow; C H Hennekens; J E Buring; W C Willett; R M Krauss
Journal:  JAMA       Date:  1988-10-07       Impact factor: 56.272

10.  High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation.

Authors:  Y Matsuda; K Hirata; N Inoue; M Suematsu; S Kawashima; H Akita; M Yokoyama
Journal:  Circ Res       Date:  1993-05       Impact factor: 17.367

View more
  3 in total

1.  The role of total and high-molecular-weight complex of adiponectin in vascular function in offspring whose parents both had type 2 diabetes.

Authors:  F Halperin; J A Beckman; M E Patti; M E Trujillo; M Garvin; M A Creager; P E Scherer; A B Goldfine
Journal:  Diabetologia       Date:  2005-08-10       Impact factor: 10.122

2.  Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB.

Authors:  L Engelbrechtsen; J Lundgren; N J Wewer Albrechtsen; Y Mahendran; E W Iepsen; P Finocchietto; A E Jonsson; S Madsbad; J J Holst; H Vestergaard; T Hansen; S S Torekov
Journal:  Obes Sci Pract       Date:  2017-11-21

3.  Single nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment.

Authors:  Ulrika Liljedahl; Lars Lind; Lisa Kurland; Lars Berglund; Thomas Kahan; Ann-Christine Syvänen
Journal:  BMC Cardiovasc Disord       Date:  2004-09-28       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.